Global Autoimmune Diseases Treatment Market Size By Type (Blood Transfusion, Supplements), By Application (Hospital, Medical Center), By Region, And Segment Forecasts, 2023 to 2032

The Global Autoimmune Diseases Treatment Market was valued at USD 56.4 billion in 2023 and is expected to surpass USD 96.7 billion by 2031, growing at a CAGR of 7.0% during the forecast period from 2023 to 2031. This market is being driven by the increasing prevalence of autoimmune conditions such as rheumatoid arthritis, lupus, and multiple sclerosis, alongside growing awareness of these diseases and advances in biologics and targeted therapies. As healthcare infrastructure continues to improve and diagnostic capabilities expand globally, early detection and timely treatment of autoimmune diseases are becoming more feasible, thus boosting market growth.

Drivers

Rising Prevalence of Autoimmune Diseases

The global burden of autoimmune disorders is steadily increasing, affecting millions of people worldwide. Conditions such as Type 1 diabetes, inflammatory bowel disease, and psoriasis are becoming more common, driving the demand for effective treatment solutions.

Advancements in Biologic and Targeted Therapies

Recent innovations in biologic drugs and targeted immune modulators have significantly improved patient outcomes. These therapies offer greater specificity with fewer side effects compared to traditional immunosuppressants, enhancing their adoption across various autoimmune indications.

Increased Healthcare Spending and Diagnosis Rates

Greater investment in healthcare infrastructure and diagnostic tools is leading to earlier and more accurate detection of autoimmune diseases. This, in turn, boosts the demand for treatment, particularly in emerging economies.

Restraints

High Cost of Biologic Therapies

The treatment of autoimmune diseases often involves expensive biologic drugs, which may not be affordable for all patients, especially in low- and middle-income countries. These high costs can hinder widespread market adoption.

Adverse Effects and Long-Term Safety Concerns

Despite their effectiveness, biologics and immunosuppressive treatments can lead to adverse effects, such as increased susceptibility to infections and potential long-term complications, limiting their use among certain patient populations.

Opportunity

Emerging Biosimilars Market

The expiration of patents for several blockbuster biologic drugs opens up significant opportunities for biosimilar manufacturers. Biosimilars can offer comparable efficacy at a lower cost, expanding treatment access.

Rising Awareness and Screening Initiatives

Public health campaigns and increasing awareness about autoimmune diseases are driving early diagnosis rates. Government and non-profit organization initiatives aimed at education and screening will continue to support market expansion.

Market by System Type Insights

By treatment type, the Biologics segment held the largest market share in 2023. Biologics have revolutionized the management of chronic autoimmune conditions by targeting specific immune system pathways, providing improved efficacy and patient outcomes. The segment is expected to continue dominating the market due to ongoing R&D and the launch of next-generation biologics.

The Corticosteroids segment, while widely used for symptom relief, is projected to grow at a slower pace due to concerns about side effects associated with long-term use.

Market by End-use Insights

In 2023, Hospitals & Clinics represented the largest end-use segment, accounting for more than 45% of the global revenue. This dominance is due to the complexity of autoimmune diseases requiring specialist care, diagnostics, and long-term treatment plans typically provided in these facilities.

Homecare settings are expected to witness accelerated growth, supported by the development of self-injectable biologics and remote patient monitoring solutions.

Market by Regional Insights

North America led the global autoimmune diseases treatment market in 2023, driven by a high prevalence of autoimmune conditions, robust healthcare infrastructure, and the presence of leading pharmaceutical companies. The U.S. remains the most lucrative market globally.

The Asia-Pacific region is anticipated to exhibit the highest growth during the forecast period. Increasing awareness, rising disposable incomes, and enhanced access to healthcare services are fueling market expansion in countries like China and India.

Competitive Scenario

Key players in the market include AbbVie Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Amgen Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., and Biogen Inc. These companies are actively engaged in strategic collaborations, R&D investment, and the launch of novel therapeutics to strengthen their competitive position.

Recent developments include:

In 2023, AbbVie launched an expanded indication for its IL-23 inhibitor Skyrizi in psoriatic arthritis.

In 2024, Novartis received FDA approval for a new biologic targeting lupus nephritis.

Biogen entered a strategic partnership in 2025 with a biotech firm to co-develop next-generation treatments for multiple sclerosis.

Scope of Work – Global Autoimmune Diseases Treatment Market

Report Metric Details

Market Size (2023) USD 56.4 billion

Projected Market Size (2031) USD 96.7 billion

CAGR (2023–2031) 7.0%

Market Segments By Treatment Type (B